GABA system as a target for new drugs

Current Medicinal Chemistry

Volumn 21, Issue 28, 2014, Pages 3294-3309

  Kowalczyk, P ^a   Kulig, K ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

GABA; GABA aminotransferaseinhibitors; GABA uptake inhibitors

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID UPTAKE INHIBITOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; HUMAN; PHYSIOLOGY;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; DRUG DESIGN; GABA UPTAKE INHIBITORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA;

EID: 84906912069     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140601202158     Document Type: Article

References (80)

1. Fagg, G. E.; Foster, A. C. Amino acid neurotransmitters and their pathways in the mammalian central nervfous system. Neuroscience, 1983, 9, 701-719.
2. Treiman, D. M. GABAergic mechanisms in epilepsy. Epilepsia, 2001, 42(Suppl. 3), 8-12.
3. Sarup, A.; Miller, O.; Schousboe, A. GABA transporters and GABA-transaminase as drug targets. Curr. Drug Targets-CNS & Neurological Disorders, 2003, 2, 269-277.
4. Madsen, K. K.; Clausen, R. P.; Larsson, O. M.; Krogsgaard-Larsen, P.; Schousboe, A.; White;H. S. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J. Neurochem., 2009, 109, 139-144.
5. Dalby, N. O. Inhibition of gamma-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur. J. Pharmacol., 2003, 479, 127-137.
6. Löscher, W. New vision of the pharmacology of anticonvulsion. Eur. J. Pharmacol., 1998, 432, 1-13.
7. A receptor: an old target with new potential? Sleep Med., 2004, 5 Suppl. 1, S9-S15.
8. Beteson, A. N. further potential of the GABA receptor in the treatment of insomnia. Sleep Med., 2006, 7 Suppl. 1, S3-S9.
9. Price, T. J.; Cervero, F.; Gold, M. S.; Hammond, D. L.; Prescott, S. A. Chloride regulation in the pain. Brain Res. Rev., 2009, 60, 149-170.
10. Enna, S. J.; Carson, K. E. The role of GABA in the mediation and perception of pain. Adv. Pharmacol, 2006, 54, 1-27.
11. Luscher, B.; Shen, Q.; Sahir, N. The GABAergic deficit hypothesis of major depressive disorder, Mol. Psychiatry, 2011, 16, 383-406.
12. Cherlyn, S. Y. T.; Woon, P. S.; Liu, J. J.; Ong, W. Y.; Tsai, G. Ch.; Sim, K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance, Neurosci. Biobehavioral Rev., 2010, 34, 958-977.
13. Krystal, JH.; Sanacora, G.; Blumberg, H.; Anand, A.; Charney, D. S.; Marek, G.; Epperson, C. N.; Goddard, A.; Mason, GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treaments. Mol. Psychiatry, 2002, 7, S71-S80.
14. Volk, D. W.; Lewis, DA. GABA targets for the treatment of cognitive dysfunction in schizophrenia. Curr. Neuropharmacol, 2005, 3, 45-62.
15. B receptor agonists, partial agonists, antagonists and modulators: design and therapeutic prospects, Eur. J. Pharm. Sci., 1997, 5, 355-384.
16. Chebib, M.; Johnston, G. A. GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology, J. Med. Chem., 2000, 43(8), 1427-1447.
17. Kumar, M. S.; Kuppast, I. J. A review on gamma-aminobutyric acid (GABA) and its receptors. Int. J. Pharm. Sci., 2012, 3, 60-69.
18. Whiting, P. J. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov. Today, 2003, 8, 445-450.
19. Jansen, M.; Rabe, H.; Strehle, A.; Dieler, S.; Debus, F.; Dannhardt, G; Akabas, M. H.; Lüddens, H. Synthesis of GABAA receptor agonists and evaluation of their alpha-subunit selectivity and orientation in the GABA binding site, J. Med. Chem., 2008, 51, 4430-4448.
20. Møller, H. A.; Sander, T.; Kristensen, J. L.; Nielsen, B.; Krall, J.; Bergmann, M. L.; Christiansen, B.; Balle, T.; Jensen, A. A.; Frølund, B. Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid (A) receptor ligands: synthesis, pharmacology, and structure-activity relationships, J. Med. Chem., 2010, 53, 3417-3421.
21. Petersen, J. G.; Bergmann, R.; Møller, H. A.; Jørgensen, C. G.; Nielsen, B.; Kehler, J.; Frydenvang, K; Kristensen, J.; Balle, T.; Jensen, A. A.; Kristiansen, U.; Frølund, B. Synthesis and biological evaluation of 4-(aminomethyl)-1-hydroxypyrazole analogues of muscimol as γ-aminobutyric acid (a) receptor agonists, J. Med. Chem., 2013, 56, 993-1006.
22. Guerrini, G.; Ciciani, G.; Cambi, G.; Bruni, F.; Selleri, S.; Melani, F.; Montali, M.; Martini, C; Ghelardini, C; Norcini, M; Costanzo, A. Novel 3-aroylpyrazolo [5, 1-c][1, 2, 4]benzotriazine 5-oxides 8-substituted, ligands at GABAA/benzodiazepine receptor complex: synthesis, pharmacological and molecular modeling studies, Bioorg. Med. Chem., 2008, 16, 4471-4489.
23. Guerrini, G.; Ciciani, G.; Cambi, G.; Bruni, F.; Selleri, S.; Melani, F.; Montali, M.; Martini, C; Ghelardini, C; Norcini, M; Costanzo, A. Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5, 1-c][1, 2, 4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism, J. Med. Chem., 2009, 52, 4668-4682.
24. Guerrini, G.; Ciciani, G.; Bruni, F.; Selleri, S.; Martini, C; Daniele, S.; Ghelardini, C; Di Cesare Mannelli, L.; Costanzo, A. Development of ligands at γ-aminobutyrric acid type A (GABAA) receptor subtype as new agents for pain relief. Bioorg. Med. Chem., 2011, 19, 7441-7452.
25. Guerrini, G.; Ciciani, G.; Costanzo, A.; Daniele, S.; Martini, C; Ghelardini, C; Di Cesare Mannelli, L.; Ciattini, S. Synthesis of novel cognition enhancers with pyrazolo[5, 1-c][1, 2, 4]benzotriazine core acting at γ-aminobutyric acid type A (GABA (A)) receptor. Bioorg. Med. Chem., 2013, 21, 2186-2198.
26. Alhambra, C; Becker, C; Blake, T.; Chang, A. H.; Damewood, J. R. Jr.; Daniels, T.; Dembofsky, B. T.; Gurley, D. A.; Hall, J. E.; Herzog, K. J.; Horchler, C. L.; Ohnmacht, C. J.; Schmiesing, R. J.; Dudley, A.; Ribadeneira, M. D.; Knappenberger, K. S.; Maciag, C; Stein, M. M.; Chopra, M.; Liu, X. F.; Christian, E. P.; Arriza, J. L.; Chapdelaine, M. J. Development and SAR of functionally selective allosteric modulators of GABAA receptors. Bioorg. Med. Chem., 2011, 19, 2927-2938.
27. Zhang, W.; Kochler, K. F.; Zhang, P.; Cook, JM. Development of a comprehensive pharmacophore model for the benzodiazepine receptor, Drug Des. Discover., 1995, 5, 193-248.
28. Kahnberg, P.; Howard, MH.; Liljefors, T.; Nielsen, M.; Nielsen, E.Ø.; Sterner, O.; Pettersson, I. The use of a pharmacophore model for ideal identification of novel ligands for benzodiazepine binding site of GABAa receptor. J. Mol Graph. Modelling, 2004, 23, 253-261.
29. Nilsson, J. Nielsen, E. Ø.; Liljefors, T.; Nielsen, M.; Sterner, O. Azaflavones compared to flavones as ligands to the benzodiazepine binding site of brain GABA (A) receptors, Bioorg. Med. Chem. Lett., 2008, 18, 5713-5716.
30. Nilsson, J.; Nielsen, E.Ø.; Liljefors, T.; Nielsen, M.; Sterner, O. 3-Alkyl- and 3-amido-isothiazoloquinolin-4-ones as ligands for the benzodiazepine site of GABA (A) receptors. Bioorg. Chem., 2012, 40, 125-130.
31. Achermann, G.; Ballard, T. M.; Blasco, F.; Broutin, P. E.; Büttelmann, B.; Fischer, H.; Graf, M.; Hernandez, M. C; Hilty, P.; Knoflach, F.; Koblet, A.; Knust, H.; Kurt, A.; Martin, J. R.; Masciadri, R.; Porter, R. H.; Stadler, H.; Thomas, A. W.; Trube, G.; Wichmann, J. Discovery of the imidazo[1, 5-a][1, 2, 4]-triazolo[1, 5-d][1, 4]benzodiazepine scaffold as a novel, potent and selective GABA (A) alpha5 inverse agonist series. Bioorg. Med. Chem. Lett., 2009, 19, 5746-5752.
32. Iqbal, F.; Ellwood, R.; Mortensen, M.; Smart, T. G.; Baker, J. R.; Synthesis and evaluation of highly potent GABA (A) receptor antagonists based on gabazine (SR-95531), Bioorg. Med. Chem. Lett., 2011, 21, 4252-4254.
33. Taferner, B.; Schuehly, W.; Huefner, A.; Baburin, I.; Wiesner, K.; Ecker, G. F.; Hering, S. Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship. J. Med. Chem., 2011, 54, 5349-5361.
34. Baulieu, E. E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23, 963-987.
35. Dubrovsky, B. O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog. Neuro-Psychopharm. Biol. Psychiatry, 2005, 29, 169-192.
36. Belelli, D.; Lambert, J J. Neurosteroids: endogenous regulators of the GABAa receptor. Nat. Rev. Neurosci., 2005, 6, 565-575.
37. Alvarez, L. D.; Veleiro, A. S.; Baggio, R. F.; Garland, M. T.; Edelsztein, V. C; Coirini, H.; Burton, G. Synthesis and GABA (A) receptor activity of oxygen-bridged neurosteroid analogs. Bioorg. Med. Chem., 2008, 16, 3831-3838.
38. Durán, F. J.; Edelsztein, V. C; Ghini, A. A.; Rey, M.; Coirini, H.; Dauban, P.; Dodd, R. H.; Burton, G. Synthesis and GABA (A) receptor activity of 2, 19-sulfamoyl analogues of allopregnanolone. Bioorg. Med. Chem., 2009, 17, 6526-6533.
39. Slavíková, B.; Bujons, J.; Matyás, L.; Vidal, M.; Babot, Z.; Kristofíková, Z.; Suñol, C; Kasal, A. Allopregnanolone and pregnanolone analogues modified in the C ring: synthesis and activity, J. Med. Chem., 2013, 56, 2323-2336.
40. Froestl, W. Chemistry and pharmacology of GABAB receptor ligands. Adv. Pharmacol, 2010, 58, 19-62.
41. B receptor trafficking and interesting proteins: Targets for the development of highly specific therapeutic strategies to treat neurological disorders. Biochem. Pharmacol, 2013, 86, 1525-1530.
42. B Receptor Function. J. Pharmacol. Exp. Ther., 2003, 307, 322-330.
43. Cryan, J. F.; Kelly, P. H.; Chaperon, F.; Gentsch, C; Mombereau, C; Lingenhoehl, K.; Froestl, W.; Bettler, B.; Kaupmann, K.; Spooren, W. P. J. M. Behavioral Characterization of the Novel GABAb Receptor-Positive Modulator GS39783 (N, N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines. J. Pharmacol. Exp. Ther., 2004, 310, 952-963.
44. Guery, S.; Floersheim, P.; Kaupmann, K.; Froestl, W. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors. Bioorg. Med. Chem. Lett., 2007, 17, 6206-6211.
45. Jay, G. W.; Barkin, R. L. Neuropathic pain: Etiology, pathophysiology, mechanisms, and evaluations. Dis. Mon., 2014, 60, 6-47.
46. Xu, F.; Peng, G.; Phan, T.; Dilip, U.; Chen, J. L.; Chernov-Rogan, T.; Zhang, X.; Grindstaff, K.; Annamalai, T.; Koller, K.; Gallop, M. A.; Wustrow, D. J. Discovery of a novel potent GABA (B) receptor agonist, Bioorg. Med. Chem. Lett., 2011, 21, 6582-6585.
47. Alstermark, C; Amin, K.; Dinn, S. R.; Elebring, T.; Fjellström, O.; Fitzpatrick, K.; Geiss, W. B.; Gottfries, J.; Guzzo, P. R.; Harding, J. P.; Holmén, A.; Kothare, M.; Lehmann, A.; Mattsson, J. P.; Nilsson, K.; Sundén, G.; Swanson, M.; von Unge, S.; Woo, A. M.; Wyle, M. J.; Zheng, X. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. J. Med. Chem., 2008, 51, 4315-4320.
48. Han, C; Salyer, A. E.; Kim, E. H.; Jiang, X.; Jarrard, R. E.; Powers, M. S.; Kirchhoff, A. M.; Salvador, T. K.; Chester, J. A.; Hockerman, G. H.; Colby, D. A. Evaluation of difluoromethyl ketones as agonists of the γ-aminobutyric acid type B (GABAB) receptor. J. Med. Chem., 2013, 56, 2456-2465.
49. Froestl, W. An historical perspective on GABAergic drugs. Future Med. Chem., 2011, 3, 163-175.
50. Madsen, C; Jensen, A. A.; Liljefors, T.; Kristiansen, U.; Nielsen, B.; Hansen, C. P.; Larsen, M.; Ebert, B.; Bang-Andersen, B.; Krogsgaard-Larsen, P.; Frølund, B. 5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid (C) receptor agonists, J. Med. Chem., 2007, 50, 4147-4161.
51. Gidal, B. E.; Privitera, M. D.; Sheth, R. D.; Gilman, J. T. Vigabatrin: A Novel Therapy for Seizure Disorders. Ann. Pharmacother., 1999, 33, 1277-1286.
52. Yuan, H.; Silverman, R. B. Structural modifications of (1S, 3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase. Bioorg. Med. Chem. Lett., 2007, 17, 1651-1654.
53. Bansal, S. K.; Sinha, B. N.; Khosa, R. L. γ-Amino butyric acid analogs as novel potent GABA-AT inhibitors: molecular docking, synthesis, and biological evaluation. Med. Chem. Res., 2013, 22, 134-146.
54. Tao, Y. H.; Xu, H. B.; Yang, X. L. Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl) propan-1-one. Bioorg. Med. Chem. Lett., 2009, 19, 731-734.
55. Kvist, T.; Christiansen, B.; Jansen, A. A.; Bräuner-Osborne, H. The four human γ-aminobutyric acid (GABA) transporters: pharmacological characterization and validation of a highly efficient screening assay. Comb. Chem. High Throughput Screen., 2009, 12, 241-249.
56. Zhou, Y.; Danbolt, N. C. GABA and glutamate transporters in brain. Front. Endocrinol, 2013, 4, 1-14.
57. Schousboe, A.; Sarup, A.; Larsson, OM.; White, H. S. GABA transporters as drug targets for modulation of GABAergic activity. Biochem. Pharmacol, 2004, 68, 1557-1563.
58. Schousboe, A.; Madsen, K. K.; White, H. S. GABA transport inhibitors and seizure protection: the past and future. Future Med. Chem., 2011, 3, 183-187.
59. Madsen, K. K.; White, H. S.; Schousboe, A. Neuronal and nonneuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther., 2010, 125, 394-401.
60. Krogsgaard-Larsen, P.; Frř, B.; Frydenvang, K. GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr. Pharm. Des., 2000, 6, 1193-1209.
61. Høg, S.; Greenwood, JR.; Madsen, K. B.; Larsson, OM.; Frølund, B.; Schousboe, A.; Krogsgsaard-Larsen, P.; Clausen, R. P. Structure-activity relationships of selective GABA uptake inhibitors. Curr. Top. Med. Chem., 2006, 6, 1861-1882.
62. Soudijn, W.; van Wijngaarden, I. The GABA transporter and ist inhibitors. Curr. Med. Chem., 2000, 7, 1063-1079.
63. Thomsen, C; Sorensen, P. O.; Egerjerg, J. 1-(3-(9H-carbazol-9-yl) - 1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter, Br. J. Pharmacol, 1997, 120, 983-985.
64. Kragel, A.; Höfner, G.; Wanner, K. T. Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. Eur. J. Pharmacol, 2005, 519, 43-47.
65. Hack, S.; Wörlein, B.; Höfner, G.; Pabel, J.; Wanner, K. T. Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors, Eur. J. Med. Chem., 2011, 46, 1483-1498.
66. White, H. S.; Watson, W. P.; Hansen, S. L.; Slough, S.; Perregaard, J.; Sarup, A.; Bolvig, T.; Petersen, G.; Larsson, O. M.; Clausen, R. P.; Frølund, B.; Falch, E.; Krogsgaard-Larsen, P.; Schousboe, A. First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J. Pharmacol. Exp. Ther., 2005, 312, 866-874.
67. Zhuang, W.; Zhao, X.; Zhao, G.; Guo, L.; Lian, Y.; Zhou, J.; Fang, D. Synthesis and biological evaluation of 4-fluoroproline and 4-fluoropyrrolidine- 2-acetic acid derivatives as new GABA uptake inhibitors. Bioorg. Med. Chem., 2009, 17, 6540-6546.
68. Faust, M. R.; Höfner, G.; Pabel, J.; Wanner, K. T. Azetidine derivatives as novel gamma-aminobutyric acid uptake inhibitors: synthesis, biological evaluation, and structure-activity relationship. Eur. J. Med. Chem., 2010, 45, 2453-2466.
69. Dhar, T. G.; Borden, L. A.; Tyagarajan, S.; Smith, K. E.; Branchek, T. A.; Weinshank, R. L.; Gluchowski, C. Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. J. Med. Chem., 1994, 37, 2334-2342.
70. Schlewer, G.; Wethmuth, C. G. Analogues tétrazoliquesd'agents GABA-mimétique. Eur. J. Med. Chem., 1984, 19, 181-186.
71. Schaffert, E. S.; Höfner, G.; Wanner, K. T. Aminomethyltetrazoles as potential inhibitors of the γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation, Bioorg. Med. Chem., 2011, 19, 6492-6504.
72. Larsson, O. M.; Falch, E.; Krogsgaard-Larsen, P.; Schousboe, A. Kinetic characterization of inhibition of gamma-aminobutyric acid uptake into cultured neurons and astrocytes by 4, 4-diphenyl-3-butenyl derivatives of nipecotic acid and guvacine, J. Neurochem., 1988, 50, 818-823.
73. Andersen, K. E.; Braestrup, C; Grønwald, F. C; Jørgensen, A. S.; Nielsen, E. B.; Sonnewald, U.; Sørensen, P. O.; Suzdak, P. D.; Knutsen, L. J. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4, 4-bis (3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate, J. Med. Chem., 1993, 36, 1716-1725.
74. Knutsen, L. J.; Andersen K. E.; Lau, J.; Lundt, B. F.; Henry, R. F.; Morton, H. E.; Naerum, L.; Petersen, H.; Stephensen, H.; Suzdak, P. D.; Swedberg, M. D.; Thomsen, C; Sørensen, P. O. Synthesis of novel GABA uptake inhibitors. 3. Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine as anticonvulsant agents, J. Med. Chem., 1999, 42, 3447-3462.
75. Pizzi, D. A.; Leslie, C. P.; Di Fabio, R.; Seri, C; Bernasconi, G.; Squaglia, M.; Carnevale, G.; Falchi, A.; Greco, E.; Mangiarini, L.; Negri, M. Stereospecific synthesis and structure-activity relationships of unsymmetrical 4, 4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 602-605.
76. Vogensen, S. B.; Jørgensen, L.; Madsen, K. K.; Borkar, N.; Wellendorph, P.; Skovgaard-Petersen, J.; Schousboe, A.; White, H. S.; Krogsgaard-Larsen, P.; Clausen, R. P. Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization. J. Med. Chem., 2013, 56, 2160-2164.
77. Pabel, J.; Faust, M.; Prehn, C; Wörlein, B.; Allmendinger, L.; Höfner, G.; Wanner, K. T. Development of an (S)-1-{2-[tris (4-methoxyphenyl) methoxy]ethyl}piperidine-3-carboxylic acid [(S) - SNAP-5114] carba analogue inhibitor for murine γ-aminobutyric acid transporter type 4. Chem. Med. Chem., 2012, 7, 1245-1255.
78. Zhao, X.; Pabel, J.; Höfner, G. C; Wanner, K. T. Synthesis and biological evaluation of 4-hydroxy-4-(4-methoxyphenyl) - substituted proline and pyrrolidin-2-ylacetic acid derivatives as GABA uptake inhibitors. Bioorg. Med. Chem., 2013, 21, 470-484.
79. Sindelar, M.; Lutz, T. A.; Petrera, M.; Wanner, K. T. Focused pseudostatichydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1. J. Med. Chem., 2013, 56, 1323-1340.
80. Silver, H.; Einoch, R.; Youdim, M.; Weinreb, O. The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions. Curr. Med. Chem., 2013, 20(3), 363-370.